This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Celldex, Hep C Bubble, Al Mann Anger

[Why not simply express the size of the hep C market opportunity in terms of percentage of GDP?]

Huge numbers like these make investors excited, so it's no surprise to hep C drug stocks going ga-ga. Gilead Sciences' (GILD - Get Report) $11 billion purchase of Pharmasset helped, so did Bristol-Myers Squibb's (BMY) $2.5 billion takeout of Inhibitex (INHX). Meantime, analysts are touting these staggering estimates to justify valuations and price tags for hep C drug stocks. Idenix Pharmaceuticals (IDIX) and Achillion Pharmaceuticals (ACHN - Get Report) are eyed as the next takeover targets.

It looks like a hep C bubble to me but, then again, I'm a natural skeptic. Here's one way I look at the situation:

Pharmasset, during its negotiations with Gilead, estimated that its hep C drugs could generate cumulative revenue of $91 billion. Compare that to cumulative sales of Pfizer's (PFE) cholesterol drug Lipitor, which totaled about $120 billion before the pill went generic.

It seems hard to believe that a hep C drug, or a combination of hep C drugs, could realistically generate revenue on par with the most successful branded commercial drug of all time. On paper it's possible, but in the real world? If the actual commercial opportunity for hep C drugs is smaller than what analysts and many investors believe it to be, then we are truly in the midst of a hep C bubble that will pop sooner or later.

None of this means, by the way, that Idenix Pharmaceuticals can't be acquired for a huge premium. Illogical acts and irrational thinking define bubbles, so I wouldn't bet against a big drugmaker, desperate to be competitive in the hep C arms race, paying up to snag Idenix and its lead drug, the "nuc" IDX184. The same can be said for Achillion Pharmaceuticals, I suppose, although Achillion's lead protease inhibitor is more of a commodity these days. The company's NS5A inhibitor, further back in development, might generate more interest.

If neither Idenix nor Achillion find buyers (which won't surprise me, either), the two companies could always merge. That might be the best idea, although speculative investors certainly hope for more.

I also totally recognize that my skepticism may be overdone and that analysts and hep C drug companies are thinking clearly about the future of hep C revenue. I launched a discussion on this topic Wednesday night on Twitter. John LaMattina, a partner at PureTech Ventures and a former top executive at Pfizer (Twitter handle: @John_LaMattina) remarked that back in the day, Pfizer execs projected peak Lipitor sales of only $800 million to $900 million.
4 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ONXX $0.00 0.00%
ACHN $6.32 -5.67%
AVNR $16.96 0.00%
CLDX $7.26 -1.63%
GILD $85.14 -1.78%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs